Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BPMC 
Blueprint Medicines Corp (BPMC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/09/2025: BPMC (4-star) is a STRONG-BUY. BUY since 45 days. Profits (26.23%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
19 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $130.6
1 Year Target Price $130.6
| 2 | Strong Buy |
| 1 | Buy |
| 15 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 83.74% | Avg. Invested days 49 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 07/09/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 8.30B USD | Price to earnings Ratio - | 1Y Target Price 130.6 |
Price to earnings Ratio - | 1Y Target Price 130.6 | ||
Volume (30-day avg) 19 | Beta 0.83 | 52 Weeks Range 73.04 - 128.78 | Updated Date 07/9/2025 |
52 Weeks Range 73.04 - 128.78 | Updated Date 07/9/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.5 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -27.7% | Operating Margin (TTM) -27.5% |
Management Effectiveness
Return on Assets (TTM) -9.75% | Return on Equity (TTM) -47.71% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 8182810729 | Price to Sales(TTM) 14.77 |
Enterprise Value 8182810729 | Price to Sales(TTM) 14.77 | ||
Enterprise Value to Revenue 14.56 | Enterprise Value to EBITDA -11.22 | Shares Outstanding 64582200 | Shares Floating 60003933 |
Shares Outstanding 64582200 | Shares Floating 60003933 | ||
Percent Insiders 0.88 | Percent Institutions 109.19 |
Upturn AI SWOT
Blueprint Medicines Corp
Company Overview
History and Background
Blueprint Medicines was founded in 2011 and focuses on developing kinase inhibitors for genomically defined cancers, rare diseases, and immune disorders. They have evolved from a research-focused company to a commercial organization with multiple approved therapies.
Core Business Areas
- Precision Oncology: Development and commercialization of targeted therapies for cancer driven by specific genetic mutations.
- Rare Diseases: Development of therapies for rare genetic disorders.
Leadership and Structure
Blueprint Medicines has a CEO and a management team overseeing various departments, including R&D, commercial operations, and finance. The organizational structure is typical for a publicly traded biopharmaceutical company.
Top Products and Market Share
Key Offerings
- Ayvakit/Ayvakyt (avapritinib): A kinase inhibitor approved for advanced gastrointestinal stromal tumor (GIST) and advanced systemic mastocytosis (AdvSM). Competitors include Novartis (Gleevec for GIST initially, but Ayvakit targets specific mutations resistant to Gleevec), and potentially other emerging therapies in AdvSM.
- Gavreto (pralsetinib): A RET inhibitor approved for RET-altered lung and thyroid cancers. Competitors include Eli Lilly's Retevmo (selpercatinib).
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, regulatory scrutiny, and competition. Precision medicine is a growing trend.
Positioning
Blueprint Medicines is a player in the precision medicine space, focusing on kinase inhibitors for genetically defined diseases. Their competitive advantage lies in their expertise in kinase biology and drug development.
Total Addressable Market (TAM)
The TAM for precision oncology and rare disease therapeutics is substantial and growing, estimated in the tens of billions of dollars annually. Blueprint Medicines is positioned to capture a share of this market with its approved therapies and pipeline.
Upturn SWOT Analysis
Strengths
- Approved therapies with demonstrated efficacy
- Strong kinase inhibitor platform
- Expertise in precision medicine
- Strategic collaborations
- Experienced management team
Weaknesses
- Reliance on a limited number of products
- Competition from larger pharmaceutical companies
- High R&D costs
- Regulatory risks
- Dependence on successful clinical trials
Opportunities
- Expansion of approved therapies to new indications
- Development of new kinase inhibitors
- Strategic partnerships and acquisitions
- Growth in precision medicine market
- Expansion into new geographic markets
Threats
- Competition from biosimilars or generics
- Unfavorable regulatory decisions
- Clinical trial failures
- Economic downturn
- Changes in healthcare reimbursement policies
Competitors and Market Share
Key Competitors
- LLY
- NVS
Competitive Landscape
Blueprint Medicines competes with larger pharmaceutical companies in the precision oncology space. Their advantage lies in their focus on kinase inhibitors and their expertise in genetically defined diseases.
Growth Trajectory and Initiatives
Historical Growth: Blueprint Medicines has experienced growth driven by the commercialization of its approved therapies.
Future Projections: Analysts project continued growth for Blueprint Medicines based on the potential of its pipeline and approved therapies.
Recent Initiatives: Recent initiatives include expanding the indications for Ayvakit/Ayvakyt and Gavreto, advancing new pipeline candidates, and forming strategic partnerships.
Summary
Blueprint Medicines is a precision medicine company focusing on kinase inhibitors. The company has commercialized therapies and boasts a growing pipeline. However, competition is stiff and regulatory hurdles exist. Their expertise in kinase biology gives them an advantage.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market conditions can change rapidly, and past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Blueprint Medicines Corp
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2015-04-30 | President, CEO & Director Ms. Kathryn Haviland M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 682 | |
Full time employees 682 | |||
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.